Performance of the VERSANT super() HIV-1 Resistance Assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes

• Published in: FEMS immunology and medical microbiology Vol. 39; no. 2; pp. 119 - 124
• Main Authors: Derdelinckx, I, Van Laethem, K, Maes, B, Schrooten, Y, De Schouwer, K, De Wit, S, Fransen, K, Garcia Ribas, S, Moutschen, M, Vaira, D, Zissis, G, Van Ranst, M, Van Wijngaerden, E, Vandamme, A
• Format: Journal Article
• Language: English
• Published: 28.11.2003
• Subjects: Human immunodeficiency virus 1; Belgium
• DOI: 10.1016/S0928-8244(03)00240-2
• ISSN: 0928-8244

In this study we evaluated the performance of the VERSANT super() HIV-1 Resistance Assays (LiPA) in detecting drug resistance in therapy-naive HIV-infected patients diagnosed in Belgium in 2000. We compared the results with population sequencing and found concordance to be in line with previous studies in treatment-experienced patients (86.87% for reverse transcriptase (RT); 92.77% for protease (PRO)). Discordance was mainly due to indeterminate reactions on LiPA (8.45% for RT; 6.85% for PRO) and minor discordances (4.13% for RT; 0.25% for PRO). Major discordances were rare (0.46% for RT; 0.12% for PRO). Indeterminate reactions were significantly associated with strains belonging to non-B subtypes.